Skip to main content
Company profile
Viatris Inc. logo

Viatris Inc.

Pipeline5 assets

  • MR-146MR-146 / AAV Gene Therapy / Ophthalmology
    Neurotrophic keratopathy (NK)
  • Low Dose Estrogen Weekly PatchEstrogen / Progestin receptors / Transdermal Patch / Women's Health
    Contraception
  • PitolisantHistamine H3 receptor / Small molecule / Neurology
    Obstructive Sleep Apnea Syndrome
  • SelatogrelP2Y12 receptor / Small molecule / Cardiovascular
    Acute Myocardial Infarction
  • CenerimodS1P1 receptor / Small molecule / Immunology
    Systemic lupus erythematosus (SLE)

Latest news9 items

All news

Viatris Reports Second-Quarter 2026 Financial Results

Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025 Adjusted EBITDA was $1.2 Billion, Up 8% Operationally Compared to Second

Viatris Announces Quarterly Dividend

PITTSBURGH, Aug. 4, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on August 3, 2026, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on September 16, 2026,

Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy

VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well Tolerated VR-205 Efficacy and Safety Profile in Japanese Patients Was Consistent with the Profile Observed in Global Studies Japanese New Drug Application Submission Targeted by End of 2026 PITTSBURGH and TOKYO, June 29, 2026

Trial Results • Phase 3Top-line results Mon, Jun 29, 2026, 6:59 AM EDT
Viatris Inc. • Endpoint Arena